Efficacy of pembrolizumab (PD-L1≥50%) versus platinum-based chemotherapy in untreated patients with advanced non-small cell lung cancer
Latest Information Update: 28 Jun 2022
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2022 Primary endpoint has not been met (Impact of BTS (defined as the sum of the dimensions of baseline target lesions according to RECIST v1.1 criteria) on OS) , Results published in the Cancer Immunology Immunotherapy
- 28 Jun 2022 Results published in the Cancer Immunology Immunotherapy
- 23 Nov 2021 New trial record